Clinical trials are not static financial environments. They are extremely change-intensive financial environments. Protocols get amended. Sites open and close. Patient enrollment accelerates or stalls. CROs revise invoices mid-study. Every one of those changes has a financial consequence, and every one of those consequences has to be tracked, reconciled, and reported — accurately, on a deadline, by a team that is almost never large enough.
For a long time, a skilled finance professional with a well-built spreadsheet could absorb that complexity. Not anymore.
Here's what the work actually looks like today. For each active trial, a finance team has to gather CRO reports, pull individual site contracts, compare patient activity data from the clinical team, and manually reconcile everything into a single spreadsheet — ticking and tying across multiple workbooks to arrive at an accrual number they can stand behind. One study, done thoroughly, consumes a full day of multiple people's time. For a company running three to five concurrent trials, quarter-end close can eat nearly a week of the finance team's calendar. Every quarter.
And that's before accounting for errors. Not because the people doing this work are careless — they are not. But because every manual reconciliation is a point of failure. A VLOOKUP pulling from the wrong workbook. A formula that didn't carry through. A CRO invoice that billed multiple patient visits at the wrong rate. These errors exist. They compound. And in many cases, nobody catches them.
Some teams try to solve this by outsourcing the manual work to a software vendor's services team. The logic is understandable, but the risk doesn't transfer with the work. Your name is still on the accruals. Your auditors still come to you, not the vendor, when a number needs to be defended. And you've inserted a human layer between your finance team and the data, which means longer cycles to get answers, to close the books, and to react when a trial's burn rate shifts. The bar for modern R&D finance isn't "faster than a spreadsheet." It's real-time visibility your team controls.
The problem is structural. Clinical trials have gotten too complex, too fast-moving, and too financially consequential for spreadsheets.
There is a better way. At Compass Therapeutics — a lean biotech managing three to five concurrent Phase 1 and Phase 2/3 trials with a two-person finance team — the old process consumed a full day per study, every close. After moving to Condor, that dropped to half a day per study, including reviewer time. Across their active portfolio, they recovered nearly a week of close time every quarter. They caught billing errors that the spreadsheet process never surfaced. They replaced site-level averaging with contract-accurate estimates for every individual site. And they absorbed additional trial volume as their portfolio grew, without adding headcount.
That's what financial infrastructure is supposed to do; it's supposed to scale with the science.
Condor's AI-powered platform automatically connects and unifies clinical, operational, and financial data from the systems and vendors R&D teams already use, eliminating the manual reconciliation layer entirely. Every accrual reflects the actual contracted rate. Every variance is visible. Every number comes with the audit trail that regulators and auditors expect. The manual work doesn't get reassigned. It gets replaced.
Spreadsheets had a good run. But their time has come and gone.
